Glycine's Role in Driving the Cognitive Symptoms of CIAS

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cognitive Impairment Associated with Schizophrenia: Pathophysiology, Diagnosis, and Emerging Treatments 

Glycine's Role in Driving the Cognitive Symptoms of CIAS

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Martin T. Strassnig, MD 
    Associate Professor 
    University of Miami Miller School of Medicine
    Miami, FL 

    No relevant relationships reported 

    Philip Harvey, PhD 
    Professor of Psychiatry and Behavioral Sciences
    Chief Director, Division of Psychology
    University of Miami Miller School of Medicine
    Miami, FL 

    Dr. Harvey has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alkermes, Boehringer-Ingelheim, Karuna Therapeutics, Merck & Co., Minerva Neurosciences, Sunovin Pharma
    Ownership Interest: i-Function, Inc.
    Royalties: WCG Endpoint Solutions 

    Content Directors, Planners, Peer Reviewers, and Relevant Staff: 

    • William Bonnelle has nothing to disclose. 
    • Cindy Davidson has nothing to disclose.  
    • Lee Harrington has nothing to disclose. 
    • Amanda Hilferty has nothing to disclose. 
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
    • Tim Person has nothing to disclose.  
    • Canan Schumann has nothing to disclose. 
    • Rosanne Strauss, PharmD, MBA has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:  

    • Provide up-to-date information on the underlying etiology that affects the onset and progression of the pathophysiology of cognitive impairment associated with schizophrenia (CIAS) 
    • Explain the impact of the economic and societal burdens of CIAS on patients and caregivers  
    • Differentiate more rapidly and accurately between the negative and cognitive symptoms caused by schizophrenia  
    • Analyze clinical trial data of the efficacy of current and emerging treatment options in controlling and managing CIAS 
    • Develop strategies to integrate new therapies into current clinical practice that manage CIAS and the negative symptoms of schizophrenia  
  • Target Audience

    This activity is designed to meet the educational needs of Psychiatry MDs, DOs, NPs, and PAs, pharmacists, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 30, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.00 contact hours/1.00 CEUs of pharmacy contact hours.1   

    The Universal Activity Number for this program is JA0006235-0000-24-052-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ( 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Jun 2024